Thermo Fisher Scientific Inc
Most Recent
FinancialsWhat Are Leon Cooperman’s Top Holdings?
In Q3, billionaire investor Leon Cooperman’s top five holdings were Fiserv, Alphabet, United Continental, Chimera Investment, and Cigna.
Company & Industry OverviewsThermo Fisher Scientific’s Gross Margin Trends
In fiscal 2018 and fiscal 2019, Thermo Fisher Scientific (TMO) is expected to generate revenue of $24.08 billion and $25.19 billion, respectively, compared with revenue of $20.92 billion in fiscal 2017.
Company & Industry OverviewsTaking Stock of Thermo Fisher as the Year Wraps Up
In this series, we’ll explore Thermo Fisher’s financials and valuation, and analysts’ views on its stock.
Company & Industry OverviewsAnalysts Remain Bullish on Illumina Stock
In November, of the 19 analysts covering Illumina (ILMN), 14 have given it “buy” or higher ratings, and five have given it “hold” ratings.
Company & Industry OverviewsUnderstanding Illumina’s Gross Margin Trend
Illumina’s cost of product revenue increased from $173.0 million in the third quarter of 2017 to $184.0 million in the third quarter of 2018.
Company & Industry OverviewsUnderstanding Illumina’s Geographical Performance
For 2018 and 2019, Illumina is expected to generate revenues of $3.33 billion and $3.80 billion, respectively.
Earnings ReportThermo Fisher Beats Analysts’ Estimates in Q3 2018 Earnings
Thermo Fisher Scientific (TMO) reported its third-quarter results today. It surpassed analysts’ estimates for EPS and revenue.
Company & Industry OverviewsHow Johnson & Johnson’s Medical Device Business Stands Now
Johnson & Johnson’s (JNJ) Medical Devices segment generated net revenues of $6.6 billion in the third quarter, reflecting ~0.2% YoY growth.
Earnings ReportThermo Fisher’s Third-Quarter Revenue Estimates
The Life Sciences Solutions segment, including reagents, instruments, and consumables, contributes ~25% of Thermo Fisher’s total revenues.
Earnings ReportWhat to Expect from Thermo Fisher’s Third-Quarter Earnings
Thermo Fisher Scientific (TMO), a leading life sciences company, is scheduled to release its third-quarter earnings on October 24.
Earnings ReportEdwards Lifesciences’ Q3 2018 Earnings Estimates
Edwards Lifesciences is expected to register third-quarter adjusted EPS of ~$1.02, a ~21% YoY (year-over-year) rise.
Earnings ReportWhat to Expect of Edwards Lifesciences’ Q3 2018 Sales
Wall Street expects Edwards Lifesciences to register sales of $0.93 billion in the third quarter, representing a YoY (year-over-year) rise of 10.8%.
Earnings ReportAnalysts Raise Target Prices on ABT ahead of Q3 Earnings
Abbott Laboratories (ABT) is slated to announce its third-quarter earnings results on October 17.
Company & Industry OverviewsWhat to Expect from Medtronic’s Diabetes Segment
In September 2018, Medtronic (MDT) announced that the company would acquire all outstanding shares of Mazor Robotics (MZOR) for $58.50 per American depository share.
Company & Industry OverviewsWhat ResMed’s Valuation Trend Indicates
The mean rating for ResMed (RMD) stock is 2.6, and its target price is $104.69.
Company & Industry OverviewsWhat Waters Corporation’s Valuation Trend Indicates
In September, of the 15 analysts covering Waters Corporation (WAT) stock, ten have given it “holds.”
Company & Industry OverviewsWhat’s the Upside Potential for Agilent Technologies Stock?
In the last three months, Agilent Technologies (A) stock has risen from $61.14 on June 27, 2018, to $70.33 in September 2018.
Company & Industry OverviewsIs Abbott Laboratories Trading at a High Valuation in September?
Abbott stock has been gaining momentum recently, and its valuation has improved.
Company & Industry OverviewsTaking Stock of Quest Diagnostics’ Recent Acquisitions
Quest Diagnostics’ (DGX) diagnostic information services (or DIS) business accounts for more than 95% of the company’s total revenues.
Company & Industry OverviewsHow Quest Diagnostics Is Positioned in 2018
Quest Diagnostics generated revenues of $1.92 billion in the second quarter of 2018 as compared with $1.86 billion in the second quarter of 2017.
Company & Industry OverviewsWhat’s the Upside Potential of Thermo Fisher Scientific Stock?
So far in 2018, Thermo Fisher Scientific (TMO) stock has generated double-digit returns for investors.
Company & Industry OverviewsWhat’s Driving the Growth in Thermo Fisher Scientific’s Segments?
Thermo Fisher Scientific (TMO) operates in four business segments.
Company & Industry OverviewsCynosure Headwinds Trigger Analyst Downgrades on HOLX Stock
As of September 18, ten of the 19 analysts that cover HOLX stock gave the company a “buy” or “strong buy” recommendation.
Company & Industry OverviewsA Look at Hologic Stock’s Recent Performance
Currently, HOLX stock is trading lower than its 50-day moving average of $39.80 but higher than its 200-day moving average of $39.16.
Company & Industry OverviewsThermo Fisher to Acquire BDX’s Advanced Bioprocessing Business
Thermo Fisher Scientific (TMO) announced on September 7, 2018, that the company would acquire the Advanced Bioprocessing Business from Becton Dickinson (BDX).
Company & Industry OverviewsThermo Fisher to Offer Complete Cannabis Testing Solutions
Thermo Fisher Scientific (TMO) announced on September 7, 2018, that the company offers end-to-end analytical solutions that comply with cannabis testing standards as defined by Health Canada.
Company & Industry OverviewsHow Thermo Fisher Scientific’s Valuation Looks in September
Thermo Fisher Scientific currently trades at a forward PE multiple of ~19.9x.
Company & Industry OverviewsHow Hologic’s Valuation Stacks Up with Peers
The company has delivered a robust financial performance in recent quarters. However, the stock has been on a bearish trend during the recent period.
Company & Industry OverviewsIllumina Stock Continues Its Bull Run
Illumina (ILMN) reached a 52-week high of $357.93 per share on August 31.
Company & Industry OverviewsA Performance Overview of Roche’s Diagnostics Division
In July, Roche received the CE Mark for its Accu-Chek Solo micropump system.
Earnings ReportWhat Analysts Recommend for Haemonetics
Wall Street analysts estimate Haemonetics’s (HAE) Q1 2019 revenues to increase ~4.3% to $219.9 million as compared to $210.9 million during Q1 2018.
Company & Industry OverviewsBoston Scientific’s Q2 2018 Adjusted EPS Exceed Guidance
In the second quarter, Boston Scientific’s adjusted EPS grew 28% YoY (year-over-year) to $0.41, exceeding its guidance of $0.33–$0.35.
Earnings ReportThermo Fisher’s Q2 2018 Estimates: Revenue Growth Expected
Wall Street analysts expect Thermo Fisher’s (TMO) revenues to reflect 18.1% growth to $5.9 billion during the second quarter.
Earnings ReportAnalyst Recommendations for TMO Stock after 1Q18 Earnings Release
As of April 25 and according to a recent Reuters survey of 16 research firms, TMO stock is rated a “strong buy” by eight analysts.
Earnings ReportThermo Fisher Scientific’s 1Q18 Sales Beat Estimates, Stock Up
On April 25, Thermo Fisher Scientific (TMO) announced its results for 1Q18. Its revenues rose 23% YoY to $5.9 billion.
Company & Industry OverviewsCan HOLX Stock Rebound from Its Recent Lows?
On March 28, 2018, Hologic (HOLX) stock ended trading at a closing price of $37.39.
Company & Industry OverviewsDiscussing BDX’s Recent Stock Price Performance
On March 28, 2018, Becton, Dickinson and Company (BDX) ended trading at a closing price of $212.43.
Company & Industry OverviewsTMO’s Advanced Laboratory Management System Could Gain Market Share
On February 27, 2018, Thermo Fisher Scientific (TMO) announced the launch of the new Thermo Scientific Chromeleon XTR Laboratory Management system, which was designed to manage an entire laboratory.
Company & Industry OverviewsHow TMO Stock Has Performed Recently
On March 14, 2018, Thermo Fisher Scientific (TMO) closed at $213.46 per share.
Company & Industry OverviewsA Look at TMO’s New High Pressure Ion Chromatography System
On February 27, 2018, Thermo Fisher Scientific (TMO) announced the launch of its new high-pressure Ion Chromatography System.
Company & Industry OverviewsA Look at Thermo Fisher Scientific’s Recent Research Partnerships
Thermo Fisher Scientific offers products including analytical instruments, reagents, equipment, and consumables, diagnostics and research software, and services.
Company & Industry OverviewsWhat Investors Should Know about TMO’s Dividends
On March 14, 2018, Thermo Fisher Scientific (TMO) stock started trading ex-dividend.
Company & Industry OverviewsWhat Are Thermo Fisher Scientific’s Current Valuations?
As of March 15, 2018, Thermo Fisher Scientific (TMO) was trading at a forward PE (price-to-earnings) ratio of 19.2x.
Company & Industry OverviewsA Look at Stryker’s Recent Dividend Announcement
On February 7, 2018, Stryker (SYK) announced a quarterly dividend of $0.47 per share.
Company & Industry OverviewsHow Tax Reform Affected Medtronic’s 3Q18 Performance
Tax reform and Medtronic’s 3Q18 results The Tax Cuts and Jobs Act was enacted in the United States in December 2017, and it seems to have affected healthcare companies’ balance sheets significantly in recently reported quarters. Most medical technology companies, including Abbott Laboratories (ABT), Boston Scientific (BSX), and Thermo Fisher Scientific (TMO), reported one-time balance sheet items related to […]
Company & Industry OverviewsAbbott Laboratories: ABT Stock’s Wall Street Recommendations
Abbott Laboratories (ABT) has recorded strong growth recently, registering stellar performance.
Company & Industry OverviewsBoston Scientific’s 4Q17 Sales Exceeded Analysts’ Estimates
Boston Scientific’s 4Q17 revenue came in at $2.41 billion, exceeding Wall Street’s estimate of ~$2.38 billion.
Company & Industry OverviewsHow Bard Acquisition Could Benefit BD
Becton Dickinson (BDX) announced its fiscal 2018 guidance, which includes the company’s recently acquired Bard business, during the company’s 1Q18 earnings release.
Company & Industry OverviewsWhat BD Expects for 2018
BD posted 1Q18 results as a standalone company and didn’t include Bard sales in 1Q18.
Company & Industry OverviewsHow BD Stock Has Performed in the Last Year
On February 6, 2018, BD released its 1Q18 earnings results, which came in ahead of expectations.
Company & Industry OverviewsWhy Abbott Laboratories Plans to Focus on Organic Growth in 2018
Abbott’s plan will be to focus on organic growth over the next year and going forward, after a slew of major acquisitions and strategic divestitures.
Earnings ReportThermo Fisher Scientific Stock Hit 52-Week High on January 23
On January 23, 2018, Thermo Fisher Scientific (TMO) traded at its 52-week high of $217.22. However, it closed at $214.55.
Earnings ReportAnalyst Ratings for Thermo Fisher Scientific before 4Q17 Results
Thermo Fisher Scientific (TMO) will announce its 4Q17 and fiscal 2017 results on January 31, 2018. It has launched some innovative products and entered into strategic collaborations and partnerships.
Company & Industry OverviewsWhat Are Accelerate Diagnostics’ Key Strengths?
In June 2017, Accelerate Diagnostics (AXDX) raised net proceeds of $83.2 million from a public offering of 2.8 million shares of common stock.
Company & Industry OverviewsDoes Accelerate Diagnostics’ Financial Performance Bode Well?
The net sales of Accelerate Diagnostics (AXDX) increased from $24,000 in 3Q16 to $828,000 in 3Q17.
Company & Industry OverviewsWhat’s the Competitive Landscape for Accelerate Diagnostics?
Accelerate Diagnostics (AXDX) currently competes with companies with automated microbiological testing products on the market like Becton Dickinson (BDX), bioMerieux, Danaher (DHR), Bruker (BRKR), Luminex (LMNX), and T2 Biosystems (TTOO).
Company & Industry OverviewsWhat Analysts Recommend for Accelerate Diagnostics and Peers
Of the four analysts covering Accelerate Diagnostics in January 2018, three analysts have given the stock a “buy” rating.
Company & Industry OverviewsStryker Stock: Wall Street Recommendations and Target Price
Stryker (SYK) offers products across its three business segments: Orthopedics, MedSurg, and Neurotechnology and Spine. The company reported strong performance across all of its business segments in fiscal 3Q17.
Company & Industry OverviewsBaxter International Expected to Post Strong 4Q17 Results
Earnings results Baxter International (BAX) is expected to announce its 4Q17 and fiscal 2017 earnings results on or around January 30, 2018. The company announced stellar 3Q17 earnings results on October 25, 2017. Year-over-year, Baxter International expects to report 4Q17 sales growth of 4%–5% and constant-currency sales growth of ~2%. However, the company’s operational sales growth, expected […]
Company & Industry OverviewsWall Street Shows Confidence in BAX Stock
Analysts’ recommendations Baxter International (BAX), one of the United States’ leading medical technology companies, offers renal and hospital solutions to healthcare providers. The company has witnessed strong growth momentum recently, and Wall Street has grown increasingly bullish on the company’s growth prospects. In this article, we’ll look at analysts’ recent recommendations, ratings, and price targets for BAX stock. […]
Company & Industry OverviewsBD’s Stock Price Performance after Recent 52-Week High
On December 28, Becton, Dickinson and Company (BDX), or BD, closed trading on the day at $214.32 per share. Currently, BD stock’s 50-day moving average stands at $221.22.
Company & Industry OverviewsA Look at Thermo Fisher Scientific’s Recent Stock Price Performance
TMO stock reported its 52-week high of $201.20 on October 26, 2017, when the company released its 3Q17 earnings results.
Company & Industry OverviewsWhy Leerink Swann Lowered Its 2018 Estimates for TMO Stock
On December 4, 2017, Leerink Swann reaffirmed its “outperform” rating on Thermo Fisher Scientific (TMO). It decreased its target price on TMO stock from $216.00 per share to $200.00 per share.
Company & Industry OverviewsWall Street Analysts’ ‘Buy’ Ratings and Recommendations on TMO Stock
On December 4, 2017, Leerink Swan reiterated its “overweight” rating on TMO stock. The investment research firm has a 12-month target price of $200.00 per share on the stock.
Company & Industry OverviewsTMO’s Acquisition from EPTEK Technology Could Boost Its China Opportunity
On December 4, 2017, Thermo Fisher Scientific (TMO) completed the acquisition of some assets from EPTEK Technology and related entities that have offices in mainland China and Taiwan.
Company & Industry OverviewsTMO’s Oncomine Dx Target Test Gets CMS Coverage
On December 7, 2017, Thermo Fisher Scientific (TMO) announced that its Oncomine Dx Target Test had been proposed for coverage by the CMS (Centers for Medicare & Medicaid Services).
Company & Industry OverviewsThermo Fisher Scientific’s Deepening Ties with Sema4
Thermo Fisher Scientific’s (TMO) Core Informatics’ Platform for Science’s modules, including a LIMS (laboratory information management system), could soon be implemented at Sema4’s two major laboratory facilities.
Company & Industry OverviewsThermo Fisher Expands Its Partnership with Genome Diagnostics
In December 2017, Thermo Fisher Scientific (TMO) expanded its partnership with Genome Diagnostics (or GenDx), a Netherlands-based firm offering molecular diagnostics solutions.
Company & Industry OverviewsTMO’s Launch of New Research Assay for Cancer
On December 7, 2017, Thermo Fisher Scientific announced the launch of a new targeted NGS (next-generation sequencing) research panel.
Company & Industry OverviewsHow Is Stryker Expected to Gain Earnings Momentum?
Overview Stryker (SYK), a leading medical technology company in the United States, has a wide portfolio of products across its three business segments: Orthopaedics, MedSurg, and NeuroTech and Spine. The company has witnessed tremendous growth over the past few years. It registered strong earnings in fiscal 3Q17 and has exceeded analysts’ estimates for the past several quarters. […]
Company & Industry OverviewsCompanion Diagnostics May Be Major Opportunity for Myriad Genetics
Myriad Genetics (MYGN) expects to attain a penetration level of 4% in the companion diagnostics segment by 2020.
Company & Industry OverviewsThis Could Be a Solid Growth Driver for Myriad Genetics in 2018
Myriad Genetics (MYGN) announced the U.S. Food and Drug Administration’s (or FDA) acceptance of its supplementary premarket approval application for BRACAnalysis CDx, a DNA sequencing companion diagnostic test.
Company & Industry OverviewsVarian’s Performance by Geography and Future Growth Potential
Varian’s Oncology segment sales in the Americas rose 2%, whereas order growth in the region rose 1% in 4Q17.
Company & Industry OverviewsCan BAX Stock Maintain Momentum after Recent Highs?
BAX stock plummeted in late 2016 but has witnessed a rise in recent months, trading at a 52-week high on October 27, 2017.
Company & Industry OverviewsBehind Baxter’s Recent Nexterone Injection Recall
On November 14, 2017, Baxter International (BAX) announced a voluntary recall of one lot of its Nexterone 150 mg/100 mL Premixed Injection.
Company & Industry OverviewsWhat’s Driving BD’s Operating Margin Expansion
Overview BD (BDX) has registered strong operating margin expansion in recent years. Its margin improved by 100 basis points in fiscal 2015 and 200 basis points in fiscal 2016. In fiscal 2017, BD’s margin expanded by ~180 basis points. In 4Q17, BD’s operating margin grew ~14.6% YoY (year-over-year), limited by 700 basis points due to the divestiture of BD’s […]
Company & Industry OverviewsUnderstanding Abbott’s Alere Acquisition: What We Can Expect
On October 3, 2017, Abbott announced the completion of its acquisition of Alere, which has had troubles since the initial announcement in February 2016.
Company & Industry OverviewsWhat’s Driving Abbott’s Diagnostic Sales and Growth Potential?
Abbott (ABT) registered sales growth of ~5% in its Diagnostics business in 3Q17. The segment’s sales were driven by a strong performance outside the US.
Company & Industry OverviewsAbbott on the Street: Analyst Recommendations
Abbott registered strong 3Q17 results, surpassing estimates for both sales and earnings and reporting healthy growth across all of its business segments.
Company & Industry OverviewsWhy Baxter’s Analysts Are Leaning toward a ‘Hold’
As of October 27, six (~35%) analysts provided a “buy” rating on the BAX stock, while ten (59%) rated the stock a “hold.”
Company & Industry OverviewsBaxter International’s Latest Guidance for Fiscal 2017
Baxter International’s sales growth guidance for fiscal 2017 is expected to be ~4% on a reported basis.
Earnings ReportHow Wall Street Views Stryker After its 3Q17 Results
Analysts’ recommendations on Stryker Stryker (SYK) announced its 3Q17 earnings results on October 26, 2017. In this article, we’ll look at analysts’ ratings, recommendations, and target prices for Stryker over the next 12 months. As of October 30, 2017, of 28 investment research companies surveyed by Reuters, 17 (61%) recommended “buy” for Stryker, nine recommended “hold,” and two recommended […]
Earnings ReportStryker Acquires Vexim: What’s the Deal?
Deal overview On October 24, 2017, Stryker (SYK) acquired the majority share capital of Vexim. The acquisition of a controlling stake in Vexim has provided Stryker with an expanded portfolio of minimally invasive technologies. SYK stock fell ~0.15% that day. The Vanguard S&P 500 ETF (VOO), which has a ~0.22% exposure to Stryker, fell ~0.23%. Following the […]
Earnings ReportCan Boston Scientific Surpass Its Earnings Estimates in 3Q17?
BSX’s EPS estimate for 3Q17 represents YoY (year-over-year) growth in the range of 9%–16%. In 2Q17, Boston Scientific registered EPS growth of 18.5% YoY.
Earnings ReportWill JNJ’s Medical Device Segment Momentum Continue in 3Q17?
Johnson & Johnson (JNJ) registered revenues of $18.8 billion, a YoY (year-over-year) increase of around 1.6% in 2Q17.
Earnings ReportAssessing Abbott’s 3Q17 Expectations by Segment
In 3Q17, the Established Pharmaceuticals segment of Abbott Laboratories is expected to report high double-digit operational sales growth.
Earnings ReportWhat to Expect from Abbott Laboratories’ 3Q17 Earnings
The 3Q17 EPS estimate for Abbott Laboratories is $0.65. The company has provided an EPS guidance range of $0.64–$0.66 for 3Q17.
Company & Industry OverviewsInside BD’s Recent Collaborations in Diagnostics
BD has a strong product pipeline of innovative products under development in its LifeSciences segment, which includes the company’s diagnostic offerings.
Company & Industry OverviewsUnderstanding BD’s Recent Stock Performance
BD has a 50-day moving average of $197.25, while its 200-day moving average is $192.35.
Company & Industry OverviewsTMO’s DNA Detection Kit Approved for FBI Use
Thermo Fisher Scientific’s Applied Biosystems DNA Kit (or Yfiler Plus PCR Amplification Kit) generates a CODIS (Combined DNA Index System) database.
Company & Industry OverviewsHow BD Is Accelerating Its Safety Revenues after Flat Growth in 3Q17
Becton Dickinson (BDX), or BD, acquired the global safety products portfolio through the acquisition of CareFusion in 2015.
Company & Industry OverviewsLatest Product Launch Expands BD’s Genomics Portfolio
Becton Dickinson accelerated its strategy to establish itself as the leader in single cell genomics with its recent launch of BD Rhapsody, a single cell analysis platform.
Company & Industry OverviewsThe Latest Analyst Recommendations for Abbott Laboratories
Abbott Laboratories (ABT) released its 2Q17 earnings results on July 20, 2017, reporting strong results for revenues as well as earnings and exceeding Wall Street’s estimates.
Company & Industry OverviewsWhat’s Expected of Baxter International in Fiscal 2017?
Baxter International (BAX) has updated its sales guidance growth from 2.0%–3.0% to approximately 4.0% on a constant currency basis.
Company & Industry OverviewsInside Baxter International’s Stock Price Performance
On September 7, 2017, BAX stock closed at $62.84 per share. It has a 50-day moving average of $61.15 and a 200-day moving average of $57.14.
Company & Industry OverviewsTaking a Look at Stryker’s Recent Stock Price Performance
On August 31, Stryker (SYK) closed trading at a closing price of $139.3. It has a 50-day moving average of $144.7 and a 200-day moving average of $137.5.
Company & Industry OverviewsWhich Way Are Zimmer Biomet’s Analysts Leaning after 2Q17?
Of the 29 brokerage firms tracking Zimmer Biomet, 18 (62%) analysts gave ZBH stock a “buy” rating, while nine (~31%) provided a “hold” rating.
Company & Industry OverviewsBecton Dickinson Raised Its 2017 Guidance, Expects Better Margins
Becton Dickinson (BDX) expects to register a strong performance in the last quarter of fiscal 2017 and thus register a robust 2017 performance.
Company & Industry OverviewsHow Innovation Is Driving Becton Dickinson’s Growth in 2017
Becton Dickinson (BDX) has seen tremendous growth in recent years, driven by some of its major acquisitions and key product launches.
Company & Industry OverviewsHow Is Becton Dickinson Progressing with Emerging Market Growth?
Becton Dickinson’s (BDX) emerging markets registered a strong double-digit growth of 10.9% in 3Q17.